[HTML][HTML] ESMO guidance for reporting oncology real-world evidence (GROW)
L Castelo-Branco, A Pellat, D Martins-Branco… - ESMO Real World Data …, 2023 - Elsevier
The use of real-world data (RWD) for generating real-world evidence (RWE) to complement
interventional clinical trial-based research is rapidly increasing. This evolving field is …
interventional clinical trial-based research is rapidly increasing. This evolving field is …
[HTML][HTML] The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering …
CB Westphalen, D Martins-Branco, JR Beal… - Annals of …, 2024 - Elsevier
Background Advances in precision oncology led to approval of tumour-agnostic molecularly
guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic …
guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic …
When to stop immunotherapy for advanced melanoma: the emulated target trials
M Amiot, L Mortier, S Dalle, O Dereure, S Dalac… - …, 2024 - thelancet.com
Summary Background Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy
with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical …
with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical …
[HTML][HTML] Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies …
JWG Derksen, D Martins-Branco, A Valachis… - ESMO Real World Data …, 2024 - Elsevier
Background The role of real-world evidence (RWE) for clinical efficacy regulatory evaluation
remains unclear. We aimed to assess and describe the reported use of RWE for clinical …
remains unclear. We aimed to assess and describe the reported use of RWE for clinical …
Preferred study designs to support a comparative therapeutic strategy question in oncology: a vignette study
A Pellat, I Boutron, E Perrodeau, R Porcher… - Journal of Clinical …, 2024 - Elsevier
Objectives Some therapeutic strategy questions in oncology could be answered with studies
using observational data. Target trial emulation is the application of design principles from …
using observational data. Target trial emulation is the application of design principles from …
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI …
A Guida, A Gili, C Mosillo, M Maruzzo, E Lai… - Clinical Genitourinary …, 2024 - Elsevier
Abstract Background Pembrolizumab/Axitinib combination is approved as first-line therapy
in mRCC. The aim of this study is to evaluate outcomes of PAXI combo in the real-world in …
in mRCC. The aim of this study is to evaluate outcomes of PAXI combo in the real-world in …
Le rôle des données de vie réelle dans la recherche en oncologie digestive: mise au point
A Pellat, T Grinda - Hépato-Gastro & Oncologie Digestive, 2024 - stm.cairn.info
1 Les études en vie réelle en oncologie, aussi connues sous le nom de real-world studies,
sont des études collectant ou analysant des données provenant de patients suivis en …
sont des études collectant ou analysant des données provenant de patients suivis en …
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design
E Fountzilas, AM Tsimberidou, HH Vo… - Cancer treatment …, 2024 - Elsevier
Choosing the right drug (s) for the right patient via advanced genomic sequencing and multi-
omic interrogation is the sine qua non of precision cancer medicine. Traditional cancer …
omic interrogation is the sine qua non of precision cancer medicine. Traditional cancer …